ClinicalTrials.gg
TerminatedNCT00812240Updated Feb 1, 2023

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

A Phase 3 interventional study of Masitinib and Imatinib in Gastrointestinal Stromal Tumors, sponsored by AB Science. Terminated at 41 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on portfolio prioritization

From the registry’s dates

  • Primary completion was Jul 2018, 8 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2019.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
335
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies in Gastrointestinal Stromal Tumors with a site in France — 8 open to participants now, 15 under way, 5 of them phase 3. Gastrointestinal Stromal Tumors · France.

Enrollment
9th of 45
335 · median 94
Started
2009
with 2 others
Phase 3
15 of 48
3 open now
Registered
14th of 48
by date
Lead sponsor
2 of 48
AB Science

Among the 48 studies in Gastrointestinal Stromal Tumors with a site in France, this one is the 9th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2009, is one of 15 in phase 3, and was the 14th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

8 of the 48 studies in Gastrointestinal Stromal Tumors with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Gastrointestinal Stromal Tumors with a site in France, or all of them as a file.
02

Study summary

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor with potent activity against wild-type c-Kit, the juxta membrane domain of c-Kit, and PDGFR. In addition to its direct inhibitory action against these kinase targets, masitinib is also thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. The objective of this prospective, multicenter, randomized, open-label, active-controlled study is to compare the efficacy and safety of masitinib with respect to imatinib in the first line treatment of gastro-intestinal stromal tumor (GIST). Treatment will be given until disease progression, limiting toxicity or patient consent withdrawal.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • Gastro-Intestinal Stromal Tumor
  • GIST
  • metastatic
  • non resectable locally advanced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria include:

  • proven, or locally advanced non resectable, or recurrent post-surgery GIST
  • Naïve patient or patient previously treated with imatinib as /adjuvant who after imatinib discontinuation
  • c-Kit (CD117) positive tumours detected by immuno-histochemically or PDGFR positive if c-Kit negative

Main exclusion criteria include:

  • Patient previously treated by tyrosine kinase inhibitors except imatinib in case of inclusion criteria
  • Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
  • Patient with active central nervous system (CNS) metastasis or with history of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
335 participants (actual)

Study arms

  • Experimental
    Masitinib (7.5)

    Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.

    Drug: Masitinib

  • Experimental
    Masitinib (6.0)

    Participants receive masitinib (6.0 mg/kg/day), given orally twice daily

    Drug: Masitinib

  • Active comparator
    Active Comparator (7.5)

    Participants receive imatinib at 400 or 600 mg per day

    Drug: Imatinib

  • Active comparator
    Active Comparator (6.0)

    Participants receive imatinib at 400 or 600 mg per day

    Drug: Imatinib

Interventions

  • Also known as: AB1010

  • imatinib 400 mg or 600 mg per day, per os

    Also known as: Gleevec

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression Free Survival is defined as the time from randomization to first documentation of objective tumor progression (date of tumor assessment documenting progressive disease assessed by CT Scan according to RECIST 1.1 and based on central review) or to death due to any cause (whichever comes first).

    Time frame: From day of randomization to disease progression or death, assessed for a maximum of 96 months]

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as time in months from the randomization date to the date of death due to any cause

    Time frame: From day of randomization to death, assessed for a maximum of 96 months

07

Study locations

41 sites
  • MD Anderson Cancer Center
    Orlando, Florida 32806, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Beth Israel Medical Center
    New York, New York 10003, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 290605, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Centre Hospitalier d'Abbeville
    Abbeville, 80142, France
  • Institut Sainte Catherine
    Avignon, 84000, France
  • Hôpital Jean Minjoz
    Besançon, 25000, France
  • Institut Bergonié
    Bordeaux, 33000, France
  • Hôpital Morvan
    Brest, 29200, France
  • Hôpitalo Henri Mondor
    Créteil, 94000, France
  • Centre Georges François Leclerc
    Dijon, 21000, France
  • Hopital Bocage
    Dijon, 21079, France
  • Centre Hospitalier Victor Jousselin
    Dreux, 28100, France
  • Clinique Pasteur
    Evreux, 27000, France
  • Centre Hospitalier de Gap
    Gap, 05000, France
  • CHD de Vendée
    La Roche sur Yon, 85925, France
  • Centre Hsopitalier de La Rochelle
    La Rochelle, 17000, France
  • Centre Hospitalier Robert Boulin
    Libourne, 33500, France
  • Centre Oscar Lambret
    Lille, 59000, France
  • Centre Léon Bérard
    Lyon, 69000, France
  • Institut Paoli Calmette
    Marseille, 13200, France
  • Centre Val d'Aurèle
    Montpellier, 34000, France
  • Centre René Gauducheau
    Nantes, 44800, France
  • Hôpital de la Source
    Orléans, 45000, France
  • Groupe Hospitalier Diaconesse Croix Saint Simon
    Paris, 75012, France
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • Hôpital Bichat Claude Bernard
    Paris, 75018, France
  • Hôpital Tenon
    Paris, 75020, France
  • Hôpital Robert Debré
    Reims, 51000, France
  • Hôpital Charles Nicolle
    Rouen, 76000, France
  • Clinique Armoricaine de Radiologie
    Saint Brieuc, 22000, France
  • Centre René Huguenin
    Saint-Cloud, 92210, France
  • Institut de Cancérologie de la Loire
    Saint-Priest-en-Jarez, 42270, France
  • Hotel Dieu de France
    Beirut, Lebanon
  • Hôpital Saint-Georges
    Beirut, Lebanon
  • Makassed General Hospital Tarik Jadide
    Beirut, Lebanon
  • Rafik Hariri University Hospital
    Beirut, Lebanon
  • Hôpital Saint-Joseph
    Jdeïdé, Lebanon
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2009 to primary completion in Jul 2018, 114 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2008
First posted
Dec 22, 2008
StartActual
Jan 2009
Primary completionActual
Jul 2018
CompletionActual
Jul 2018
Results delay requested
Nov 28, 2019
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00812240
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Dec 22, 2008
Start date
Jan 2009
Primary completion
Jul 2018
Completion
Jul 2018
Last update
Feb 1, 2023

Study contacts

Antoine Adenis, MD
principal investigator · Centre Oscar Lambret, Lille, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion